{"id":"W4311621329","doi":"10.1136/ard-2022-222543","title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eli Lilly Japan; Genentech; Idorsia Pharmaceuticals; Teijin Pharma; Taichung Veterans General Hospital; Assistance publique-Hôpitaux de Paris; Chugai Pharmaceutical; National Yang-Ming University; Duke Clinical Research Institute; Astellas Pharma; Eisai; Mitsubishi Tanabe Pharma Corporation; Medicines Company; Regado Biosciences; St. Jude Medical; Nippon Shinyaku; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Regeneron Pharmaceuticals; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Belvoir Media Group; Boehringer Ingelheim Japan; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Gilead Sciences; Bristol-Myers Squibb; Cleveland Clinic; Actelion Pharmaceuticals; Ministry of Science and Technology, Taiwan; Moderna; Pfizer; Biogen; HLS Therapeutics; GlaxoSmithKline; CSL Behring; Eli Lilly and Company; Amgen; Sanofi; American Heart Association","keywords":"Medicine; Tofacitinib; Rheumatoid arthritis; Open label; Malignancy; Internal medicine; Dermatology; Randomized controlled trial; TNF inhibitor; Clinical trial; Arthritis; Oncology; Adalimumab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002333404,0.000338156,0.001420366,0.0001057822,0.0005897694,0.0001510511,0.001010931,0.00004607999,0.0004735825],"category_scores_gemma":[0.006681166,0.000187558,0.0003161227,0.0005691513,0.000434254,0.0002242495,0.0004200418,0.0004293456,0.000009581924],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003516188,"about_ca_system_score_gemma":0.000599678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002211972,"about_ca_topic_score_gemma":0.0006163081,"domain_scores_codex":[0.9941118,0.002258125,0.001315197,0.0004726764,0.001271705,0.0005705365],"domain_scores_gemma":[0.9935341,0.00409856,0.000861666,0.001076669,0.0002028941,0.0002261094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9461612,0.001792675,0.005327177,0.0000236604,0.001073993,0.00003937745,0.001135545,0.0001790836,0.000009519578,0.0001995518,0.01041124,0.03364698],"study_design_scores_gemma":[0.9801711,0.002236197,0.009526576,0.001719265,0.00002686714,0.00001183249,0.002383495,0.0003838743,0.0001188846,0.001562016,0.001566887,0.0002929584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9662449,0.02033719,0.00000230812,0.004066564,0.0005717151,0.005736059,0.002367745,0.00004436226,0.000629107],"genre_scores_gemma":[0.9691026,0.02900057,0.00002993393,0.000237659,0.00004578207,0.001301509,0.0001734479,0.00004274251,0.00006572977],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03400996,"threshold_uncertainty_score":0.7998462,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05098159510434724,"score_gpt":0.3178714133574589,"score_spread":0.2668898182531116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}